GET DAILY SIGNALSEli Lilly (LLY) Advances +24% on Strong Q3 Results and Raised Guidance
Key Takeaways
- Shares of Eli Lilly rose roughly 24% over the past 30 days, supported by a solid third-quarter earnings beat and an upward revision to full-year revenue expectations.
- Third-quarter 2026 revenue grew 39% year over year to approximately $24.4 billion, with adjusted earnings per share coming in at $7.48, both ahead of analyst estimates.
- Sales of the GLP-1 treatments Mounjaro increased 65% and Zepbound rose 49%, together representing about two-thirds of the quarter’s revenue.
- The company lifted its 2026 full-year revenue forecast to a range of $91–92 billion, up from the prior $85–87 billion guidance, adding roughly $5.5 billion at the midpoint.
- Encouraging head-to-head Phase 3 results for retatrutide against Novo Nordisk’s Ozempic provided additional support for the stock.
- Further details on valuation, earnings history, and projections are available on the dedicated Price Targets, Earnings, and Forecast pages.
Eli Lilly’s Market Position and Product Portfolio
Eli Lilly and Company, based in Indianapolis, maintains a leading position in pharmaceuticals with key offerings across diabetes, obesity, oncology, immunology, and neuroscience. Its metabolic therapies Mounjaro for type 2 diabetes and Zepbound for weight management have become primary growth drivers. The company also markets Verzenio, Ebglyss, and Kisunla while advancing candidates such as retatrutide and the oral GLP-1 treatment Foundayo. I often cross-reference industry comparisons using Tickeron’s AI Screener when evaluating how LLY stacks up against peers.
Recent Stock Price Movement Over 30 Days and the Quarter
Over the past 30 days, Eli Lilly shares advanced approximately 24%, moving from a closing price near $1,143 in early October to a record close around $1,418. The gains picked up pace in the latter half of the month after the earnings release. On a quarterly basis, the stock climbed roughly 26% from a level near $1,121 in early August, reflecting steady investor confidence in GLP-1 demand, expanded Medicare coverage, and ongoing pipeline progress. I checked the broader sector context with Tickeron’s AI Trend Prediction Engine to see how the move aligned with industry peers.
Factors Behind the 30-Day Advance
The primary catalyst came from the third-quarter 2026 earnings report released on October 29. Revenue rose 39% year over year to about $24.4 billion, surpassing consensus estimates near $22.6 billion, while adjusted earnings per share reached $7.48. Mounjaro revenue jumped 65% to roughly $10.7 billion, and Zepbound revenue increased 49% to about $5.35 billion. Management raised full-year revenue guidance to $91–92 billion, citing strong uptake of the Medicare GLP-1 Bridge Program and international demand. Positive Phase 3 data showed retatrutide delivered greater A1C reduction and weight loss than Ozempic, prompting several firms including Scotiabank, Truist, and RBC to raise price targets into the $1,600 range. The oral GLP-1 launch Foundayo contributed about $184 million, which fell short of some expectations and tempered enthusiasm somewhat.
Drivers of Quarterly Performance
The three-month gain reflects broader momentum in metabolic-drug demand and improved market access. Since the July 1 launch of the Medicare GLP-1 Bridge Program, more than half a million prescriptions have been filled through the program, with a meaningful portion involving Lilly obesity treatments. International volume growth and manufacturing expansions in Texas and Virginia have also contributed. A modest reduction in adjusted EPS guidance tied to acquired IPR&D charges created some near-term noise, yet the market has focused on the durability of top-line expansion.
Key Areas to Monitor Going Forward
Several elements will likely influence the path ahead. The ongoing commercialization of Foundayo remains a focal point after its initial launch performance. Progress on retatrutide and other late-stage assets, manufacturing capacity updates, and continued Medicare program uptake will be important to watch. Competitive dynamics with Novo Nordisk in both injectable and oral treatments represent another variable. The company’s next investor update and initial 2027 guidance should offer more clarity on growth sustainability. From what I see, these factors warrant close attention without constituting investment advice.
Reviewing AI-Driven Trading Approaches
I’ve found Tickeron’s Trending AI Robots page helpful when looking for a focused selection of automated strategies. It highlights top-performing bots from a larger platform, showing different methodologies, holding periods, and recent results. This offers a practical way to compare data-driven options that have shown relevance lately and can serve as a complement to traditional analysis when evaluating trading ideas.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
LLY in upward trend: 10-day moving average broke above 50-day moving average on October 15, 2026
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 51 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 231 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (37.123) is slightly higher than the industry average of (-1.476). P/E Ratio (47.269) is within average values for comparable stocks, (21.871). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.038) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement